site logo

ESMO21: Mirati sets new KRAS bar, AstraZeneca's breast cancer data and Keytruda challengers line up

Mirati's drug looks to have an edge over Amgen's, while AstraZeneca and Daiichi reported impressive data for Enhertu.

European Society for Medical Oncology